Telix Pharmaceuticals Ltd. (AU:TLX)
OTHER OTC:TLX
Want to see AU:TLX full AI Analyst Report?
Top Page
Telix Pharmaceuticals
(OTC:TLX)
Select Model
Select Model
Rating:60Neutral
Price Target:
AU$15.00
â–²(2.46% Upside)
Action:Reiterated
Date:03/26/26
The score is primarily held back by weaker financial quality signals—negative 2025 cash flow, a return to net loss, and rising leverage—despite strong multi-year revenue growth. Offsetting this are constructive technical momentum and a supportive earnings call with upbeat FY2026 growth guidance, though valuation metrics are unfavorable given the negative P/E and no dividend yield.
Positive Factors
Sustained Revenue Growth
Telix has delivered multi-year double-digit revenue expansion and guided another ~20% growth for FY2026. Durable top-line momentum reflects expanding commercial adoption, broader product mix and international roll-outs, supporting scale benefits for operations, R&D funding and long-term market share gains.
Negative Factors
Rising Leverage
Leverage has increased materially over recent years with debt exceeding equity, reducing financial flexibility. If earnings or cash conversion weaken, elevated debt raises refinancing and covenant risk and constrains discretionary spending, making capital allocation more sensitive to execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Telix has delivered multi-year double-digit revenue expansion and guided another ~20% growth for FY2026. Durable top-line momentum reflects expanding commercial adoption, broader product mix and international roll-outs, supporting scale benefits for operations, R&D funding and long-term market share gains.
Read all positive factors
Telix Pharmaceuticals (TLX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.92B
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth59.13%
EPS Growth-121.52%
CountryAU
Employees415
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding339,378,850
10 Day Avg. Volume2,260,784
30 Day Avg. Volume1,957,551
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$25.20Price Target Upside72.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.04
Revenue Forecast (FY)AU$967.95M
Telix Pharmaceuticals Business Overview & Revenue Model
Company Description
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare con...
How the Company Makes Money
Telix makes money primarily through the commercial sale of its radiopharmaceutical products, supplemented by other income streams tied to its development and commercial infrastructure.
1) Product sales (core revenue stream)
- Telix’s main source ...
Telix Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 20, 2026
Earnings Call Sentiment Positive
The call presents a predominantly positive commercial and strategic picture: very strong top-line growth (56% FY2025), a high-margin, cash-generative Precision Medicine engine, successful recent FDA approval and launches, a deep late-stage pipeline with three pivotal therapeutic programs, and upgraded R&D investment to accelerate therapeutics. Offsetting these strengths are regulatory setbacks that require resubmissions (Pixclara and Zircaix), modest consolidated profitability due to aggressive reinvestment (adjusted EBITDA $39.5M), a lean year-end cash balance after major investments, and near-term concentration in the U.S. reimbursement environment. Management has outlined a clear plan to self-fund pipeline advancement and scale manufacturing, but execution and timing of regulatory approvals and the ramp of international reimbursement remain key risks.Positive Updates
Strong Revenue Growth
Total FY2025 revenue grew 56% year-over-year to $804 million (third consecutive year of double-digit revenue growth), in line with guidance; FY2026 revenue guidance set at $950–$970 million (roughly 20%+ growth).
Negative Updates
Regulatory Setbacks and Resubmissions
Pixclara (Pixlumi) and Zircaix did not gain approval in the prior year and require resubmissions; company cites FDA process turbulence and has undertaken management and regulatory capability changes but expects resubmissions and approvals in 2026 (timing remains an execution risk).
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Total FY2025 revenue grew 56% year-over-year to $804 million (third consecutive year of double-digit revenue growth), in line with guidance; FY2026 revenue guidance set at $950–$970 million (roughly 20%+ growth).
Read all positive updates
Company Guidance
The company guided to FY2026 revenue of $950–$970 million (roughly 20%+ growth versus FY25), with Precision Medicine expected to grow up to ~25% (baseline 15–20% annualized, potentially ~30% CAGR with indication expansion and ~40% including Pixclara and Zircaix); R&D investment is planned at $200–$240 million in 2026 (after $157 million invested in 2025), and the 2026 revenue range excludes incremental contributions from pending approvals. For context FY2025 results were revenue $804 million (+56% YoY), Precision Medicine revenue $622 million (+22% YoY) with Precision Medicine EBITDA of $216 million (+25%), group gross margin ~53% (≈94% of gross margin, about $400 million, generated by Precision Medicine), adjusted EBITDA $39.5 million, operating cash flow $206 million (net positive operating cash flow of $35 million excluding a $52 million contingent payment), ending cash $142 million, and the company noted it has reinvested ~$0.5 billion into the business—emphasizing discretionary R&D spend linked to commercial performance.Telix Pharmaceuticals Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
52
Neutral
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.25B | 783.21M | 502.55M | 160.10M | 7.60M |
| Gross Profit | 662.07M | 509.68M | 314.39M | 29.34M | -29.77M |
| EBITDA | 61.33M | 87.58M | 22.97M | -92.84M | -70.07M |
| Net Income | -11.05M | 49.92M | 5.21M | -104.08M | -80.51M |
Balance Sheet | |||||
| Total Assets | 1.77B | 1.52B | 409.88M | 255.35M | 109.81M |
| Cash, Cash Equivalents and Short-Term Investments | 212.74M | 710.35M | 123.24M | 116.33M | 22.04M |
| Total Debt | 699.77M | 581.45M | 17.45M | 10.45M | 2.54M |
| Total Liabilities | 1.15B | 948.22M | 249.39M | 175.35M | 106.17M |
| Stockholders Equity | 622.89M | 568.21M | 148.91M | 80.01M | 2.16M |
Cash Flow | |||||
| Free Cash Flow | -85.62M | 9.00M | 13.09M | -77.83M | -60.67M |
| Operating Cash Flow | -26.82M | 43.03M | 23.88M | -63.97M | -59.33M |
| Investing Cash Flow | -443.42M | -135.17M | -25.49M | -17.00M | -2.73M |
| Financing Cash Flow | -5.77M | 638.92M | 10.19M | 174.96M | 2.85M |
Telix Pharmaceuticals Technical Analysis
Positive
14.64
Price Trends
14.25
Positive
12.61
Positive
13.33
Positive
Market Momentum
0.05
Negative
61.70
Neutral
87.78
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TLX, the sentiment is Positive. The current price of 14.64 is above the 20-day moving average (MA) of 13.41, above the 50-day MA of 14.25, and above the 200-day MA of 13.33, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 61.70 is Neutral, neither overbought nor oversold. The STOCH value of 87.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:TLX.
Telix Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$4.92B | -451.47 | -1.72% | ― | 59.13% | -121.52% | |
55 Neutral | AU$70.88M | -1.58 | -93.08% | ― | 116.02% | 75.56% | |
54 Neutral | AU$476.45M | -45.16 | -47.44% | ― | ― | -15.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$809.35M | -8.32 | -59.59% | ― | ― | -70.72% | |
41 Neutral | AU$47.82M | -0.50 | -134.65% | ― | ― | 62.72% | |
40 Underperform | AU$78.11M | -0.86 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:TLX
Telix Pharmaceuticals
14.50
-9.98
-40.77%
AU:IMU
Imugene
0.12
-0.33
-73.98%
AU:IMM
Immutep Ltd
0.05
-0.17
-76.44%
AU:RAC
Race Oncology Ltd.
2.43
1.15
89.84%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.17
0.16
7.96%
AU:RAD
Radiopharm Theranostics Limited
0.02
>-0.01
-13.04%
Telix Pharmaceuticals Corporate Events
Telix Director David Gill Increases Stake With Nasdaq ADS Purchase
Jun 16, 2026
Telix Pharmaceuticals has disclosed a change in the holdings of director David Gill, who has increased his direct interest in the company via an on-market purchase of American Depositary Shares on Nasdaq. Gill acquired 10,200 ADS at a price of US$...
Telix Issues New Tranche of Unquoted Equity Under Employee Incentive Schemes
Jun 1, 2026
Telix Pharmaceuticals has issued a new tranche of unquoted equity securities under its employee incentive schemes, covering various forms of rights for staff in different jurisdictions. The company created 27,121 deferred share rights for ex-U.S. ...
Telix boosts CEO equity incentives with new long-term rights grant
Jun 1, 2026
Telix Pharmaceuticals has disclosed changes to the holdings of Managing Director and CEO Dr Christian Behrenbruch, reflecting the grant of additional performance share appreciation rights and deferred share rights approved at the company’s 2...
Telix Grants Share Appreciation Rights to Director Marie McDonald
Jun 1, 2026
Telix Pharmaceuticals has disclosed a change in director Marie McDonald’s interests, following the grant of 23,139 Share Appreciation Rights under the company’s Equity Incentive Plan. The award, approved by shareholders at the 21 May 2...
Telix Grants Share Appreciation Rights to Director Jellison After AGM Approval
Jun 1, 2026
Telix Pharmaceuticals has granted 21,597 Share Appreciation Rights to director William Jellison under its Equity Incentive Plan, following shareholder approval at the company’s 2026 Annual General Meeting. The rights, which carry a notional ...
Telix Grants Share Appreciation Rights to Director Maria Rivas
Jun 1, 2026
Telix Pharmaceuticals has updated the market on the equity interests of non-executive director Maria Rivas, confirming the grant of 21,597 Share Appreciation Rights under its Equity Incentive Plan. The allocation, approved by shareholders at the 2...
Telix Grants Share Appreciation Rights to Director David Gill
Jun 1, 2026
Telix Pharmaceuticals has granted 30,048 Share Appreciation Rights to director David Gill under its Equity Incentive Plan, following shareholder approval at the company’s 2026 Annual General Meeting. The rights, which carry a notional exerci...
Telix Shareholders Back All Resolutions at Annual General Meeting
May 21, 2026
Telix Pharmaceuticals reported that all resolutions presented at its annual general meeting in Melbourne were passed by shareholders via poll, signaling broad investor support for the company’s current strategy and governance. The successful...
Telix underscores radiopharma portfolio and regulatory risks at shareholder meeting
May 21, 2026
Telix Pharmaceuticals used its latest shareholder meeting materials to highlight the breadth of its approved and investigational radiopharmaceutical portfolio, led by Illuccix and supported by imaging agents like Scintimun and the SENSEI surgical ...
Telix boosts radiopharma scale and pivots deeper into cancer therapeutics
May 21, 2026
Telix used its 2025 Annual General Meeting to highlight strong commercial momentum, reporting 2025 group revenue of US$804 million, up 56% year-on-year, driven by Illuccix and the launch of Gozellix. First-quarter 2026 revenue rose to US$230 milli...
Telix Issues New Shares to Complete Deferred ImaginAb Acquisition Payment
May 8, 2026
Telix Pharmaceuticals has issued 264,943 fully paid ordinary shares to satisfy a US$4 million deferred payment related to its acquisition of U.S.-based ImaginAb, Inc., a deal previously disclosed to the market. The company stated that the shares w...
Telix Seeks ASX Quotation for Additional Ordinary Shares
May 8, 2026
Telix Pharmaceuticals has applied for quotation on the ASX of 264,943 new fully paid ordinary shares, expanding its listed securities base. The additional shares, issued under previously announced transactions, modestly increase Telix’s equi...
Challenger exits substantial holder position in Telix Pharmaceuticals
May 6, 2026
Challenger Limited, a major Australian investment and financial services group, has filed a notice with the ASX confirming it has ceased to be a substantial shareholder in Telix Pharmaceuticals. The change reflects a reduction in Challenger’...
Telix to Release Escrowed Shares from Lightpoint Acquisition
Apr 29, 2026
Telix Pharmaceuticals has announced that 45,584 ordinary shares issued to Lightpoint Medical as part of the acquisition of its SENSEI radio-guided surgery business will be released from voluntary escrow on 6 May 2026. The scheduled escrow expiry m...
Telix to Spotlight Next‑Generation PSMA Therapy Portfolio in Investor Webinar
Apr 27, 2026
Telix Pharmaceuticals will host an investor webinar examining the evolution of PSMA-targeted radionuclide therapy and its multi-product strategy for treating prostate cancer across the disease continuum. The event, led by Group Chief Medical Offic...
Telix Pharmaceuticals Issues New Tranche of Unquoted Convertible Notes
Apr 23, 2026
Telix Pharmaceuticals Limited has notified the market of the issuance of an additional tranche of unquoted convertible notes. The company will issue 3,000 convertible notes, due on 22 April 2031, with the notes recorded as being issued on 22 April...
Telix Reshapes Capital Structure With US$600m Convertible Issue and Bond Buyback
Apr 23, 2026
Telix Pharmaceuticals has settled a US$600 million issuance of 1.50% convertible notes due 2031 through its U.S. investment subsidiary, with the bonds expected to list on the Singapore Exchange. The transaction, led by J.P. Morgan as sole bookrunn...
Telix Sets Hybrid 2026 AGM to Engage Global Investor Base
Apr 20, 2026
Telix Pharmaceuticals has scheduled its 2026 Annual General Meeting for May 21 in Melbourne, offering both in-person attendance at The Events Centre on Collins Street and online participation via a dedicated webcast platform. The company has distr...
Telix raises US$600m via new convertible notes to refinance 2029 bonds
Apr 20, 2026
Telix Pharmaceuticals has detailed the issuance of US$600 million in 1.50% senior unsecured convertible notes due 2031 via its wholly owned subsidiary, Telix Pharmaceuticals (Investments) Inc., with guarantees from Telix and its U.S. arm. The note...
Telix Issues New Unquoted Share Rights Under Employee Incentive Scheme
Apr 16, 2026
Telix Pharmaceuticals has notified the market of the issue of new unquoted share rights under its employee incentive scheme, reflecting ongoing use of equity-based compensation to retain and motivate staff. The company will issue 79,750 share righ...
Telix Reports Lapse of Share Appreciation and Performance Rights
Apr 16, 2026
Telix Pharmaceuticals has notified the market of the cessation of certain equity incentive instruments, specifically 173,861 share appreciation rights (code TLXAO) and 43,428 performance share appreciation rights (code TLXAW). These instruments la...
Telix Pharmaceuticals Files Appendix 3B for Proposed Securities Issue
Apr 14, 2026
Telix Pharmaceuticals has lodged an Appendix 3B with the ASX outlining a proposed issue of securities by the company. The filing indicates Telix is seeking quotation of the new securities on the exchange in line with ASX Listing Rules, signalling ...
Telix Upsizes US$600m Convertible Bond to Refinance 2029 Notes
Apr 14, 2026
Telix Pharmaceuticals has priced and upsized a new five-year US$600 million issue of 1.50% convertible bonds, following strong global investor demand, with the notes convertible into ordinary shares at a 37.5% premium to the A$14.22 reference pric...
Telix Showcases Glioblastoma Case Response and Details Offshore Convertible Bond Offer
Apr 14, 2026
Telix Pharmaceuticals has highlighted clinical imaging data showing a patient with recurrent glioblastoma who achieved a near-complete response after treatment with its investigational LAT1-targeted radiotherapeutic, TLX101-Tx. The case, published...
Telix Raises US$550m in Convertible Note Refi to Extend Debt Maturity
Apr 14, 2026
Telix Pharmaceuticals has launched a US$550 million offering of five‑year convertible notes due 2031, issued via its U.S. investment subsidiary and guaranteed by the parent company and its U.S. unit, as part of a proactive refinancing of its...
Telix and Regeneron Strike Global Radiopharma Alliance in Precision Oncology Push
Apr 12, 2026
Telix Pharmaceuticals and Regeneron Pharmaceuticals have entered a strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies for solid tumors, combining Telix’s radiopharmaceutical development a...
Citi Group Entities Drop Below Substantial Holder Threshold in Telix Pharmaceuticals
Apr 10, 2026
Citigroup Global Markets Australia and related Citi group entities have notified Telix Pharmaceuticals that they have ceased to be a substantial holder in the company as of 8 April 2026. The change reflects net reductions in their relevant interes...
FDA Accepts Telix NDA for Glioma Imaging Agent TLX101-Px
Apr 9, 2026
Telix Pharmaceuticals has had its resubmitted New Drug Application for TLX101-Px (Pixclara), an F-18 FET PET imaging agent for glioma, accepted by the U.S. FDA, which set a PDUFA goal date of September 11, 2026. The agent, already supported by int...
Telix Issues 10,000 New Shares Following Conversion of Unquoted Securities
Apr 9, 2026
Telix Pharmaceuticals has issued 10,000 new fully paid ordinary shares following the exercise or conversion of previously unquoted options or other unquoted convertible securities. The issuance, dated 23 March 2026 and formally notified to the mar...
Telix Seeks ASX Quotation for Additional Ordinary Shares
Apr 9, 2026
Telix Pharmaceuticals has applied for quotation on the ASX of an additional 222,840 ordinary fully paid shares, issued following the exercise or conversion of existing options or other convertible securities. The new shares, dated 19 and 31 March ...
Telix Adds High-Profile Directors to Bolster Global Biopharma Push
Apr 8, 2026
Telix Pharmaceuticals has expanded its board with the appointment of two additional non-executive directors, Maria Rivas and William Jellison, effective May 11, 2026, as part of a broader expansion and succession plan. Rivas brings extensive exper...
Challenger Exits Substantial Holder Position in Telix Pharmaceuticals
Apr 7, 2026
Challenger Limited has notified the Australian Securities Exchange that it and its associated entities have ceased to be substantial holders in Telix Pharmaceuticals. The change in holding status was formalised via a statutory notice of ceasing to...
Telix boosts Q1 revenue and advances global radiopharma pipeline
Apr 6, 2026
Telix Pharmaceuticals reported unaudited first-quarter 2026 group revenue of US$230 million, up 11% sequentially and 24% year-on-year, with its Precision Medicine segment growing 16% quarter-on-quarter on strong Illuccix and Gozellix sales. The co...
Citi Group Entities Exit Substantial Holder Status in Telix Pharmaceuticals
Apr 2, 2026
Citigroup Global Markets Australia and related Citi group entities have notified Telix Pharmaceuticals that they have ceased to be a substantial holder in the company as of 31 March 2026. The change reflects a series of adjustments in relevant int...
Telix strengthens board with David Gill appointment amid governance reshuffle
Apr 2, 2026
Telix Pharmaceuticals has appointed veteran life sciences executive David Gill as a Non-Executive Director, effective May 11, 2026, as part of a broader board expansion and succession plan. Gill, who has extensive experience in biopharmaceuticals,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.